Synonym
Alfetim; alfusozine; alfuzosin; alfuzosin hydrochloride; alphuzosine; Benestan; N-(3-((4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-2-furancarboxamide; Urion; UroXatral; Xatral
IUPAC/Chemical Name
N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furancarboxamide, monohydrochloride
InChi Key
YTNKWDJILNVLGX-UHFFFAOYSA-N
InChi Code
InChI=1S/C19H27N5O4.ClH/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19;/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23);1H
SMILES Code
O=C(C1OCCC1)NCCCN(C2=NC(N)=C3C=C(OC)C(OC)=CC3=N2)C.[H]Cl
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
389.46
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Alfuzosin. 2018 Jan 8. PMID: 31644057.
2: Mari A, Antonelli A, Cindolo L, Fusco F, Minervini A, De Nunzio C. Alfuzosin for the medical treatment of benign prostatic hyperplasia and lower urinary tract symptoms: a systematic review of the literature and narrative synthesis. Ther Adv Urol. 2021 Apr 12;13:1756287221993283. doi: 10.1177/1756287221993283. PMID: 33912246; PMCID: PMC8047826.
3: Yeung HEL, Sena SJ, Calopedos RJ, Woo HH. Alfuzosin and Its Effect on Ejaculatory Dysfunction: A Systematic Review. World J Mens Health. 2021 Apr;39(2):186-194. doi: 10.5534/wjmh.180024. Epub 2020 Jan 2. PMID: 32009306; PMCID: PMC7994660.
4: Manjunatha R, Pundarikaksha HP, Madhusudhana HR, Amarkumar J, Hanumantharaju BK. A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia. Indian J Pharmacol. 2016 Mar-Apr;48(2):134-40. doi: 10.4103/0253-7613.178825. PMID: 27127315; PMCID: PMC4825428.
5: Cho KJ, Kim JC. Alfuzosin for the treatment of storage symptoms suggestive of overactive bladder. Expert Opin Pharmacother. 2012 Jun;13(8):1143-51. doi: 10.1517/14656566.2012.682149. PMID: 22594844.
6: Lee M. Alfuzosin hydrochloride for the treatment of benign prostatic hyperplasia. Am J Health Syst Pharm. 2003 Jul 15;60(14):1426-39. doi: 10.1093/ajhp/60.14.1426. Erratum in: Am J Health Syst Pharm. 2004 Mar 1;61(5):437. PMID: 12892027.
7: McVary KT. Alfuzosin for symptomatic benign prostatic hyperplasia: long-term experience. J Urol. 2006 Jan;175(1):35-42. doi: 10.1016/S0022-5347(05)00032-7. PMID: 16406865.
8: Höfner K, Jonas U. Alfuzosin: a clinically uroselective alpha1-blocker. World J Urol. 2002 Apr;19(6):405-12. PMID: 12022709.
9: McKeage K, Plosker GL. Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs. 2002;62(4):633-53. doi: 10.2165/00003495-200262040-00009. PMID: 11893233.
10: Wilde MI, Fitton A, McTavish D. Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs. 1993 Mar;45(3):410-29. doi: 10.2165/00003495-199345030-00008. PMID: 7682910.
11: Weiner DM, Lowe FC. Alfuzosin for the management of benign prostate hyperplasia. Expert Opin Pharmacother. 2003 Nov;4(11):2057-63. doi: 10.1517/14656566.4.11.2057. PMID: 14596659.
12: MacDonald R, Wilt TJ. Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects. Urology. 2005 Oct;66(4):780-8. doi: 10.1016/j.urology.2005.05.001. PMID: 16230138.
13: Roehrborn CG. Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker. Urology. 2001 Dec;58(6 Suppl 1):55-63; discussion 63-4. doi: 10.1016/s0090-4295(01)01322-x. PMID: 11750253.
14: Zabala S, Thomson C, Valdearcos S, Gascón A, Pina MA. Alfuzosin-induced hepatotoxicity. J Clin Pharm Ther. 2000 Feb;25(1):73-4. doi: 10.1046/j.1365-2710.2000.00259.x. PMID: 10771467.
15: Vela-Casasempere P, Borras-Blasco J, Navarro-Ruiz A. Alfuzosin-associated dermatomyositis. Br J Rheumatol. 1998 Oct;37(10):1135-6. doi: 10.1093/rheumatology/37.10.1135. PMID: 9825757.
16: Liu C, Zeng G, Kang R, Wu W, Li J, Chen K, Wan SP. Efficacy and Safety of Alfuzosin as Medical Expulsive Therapy for Ureteral Stones: A Systematic Review and Meta-Analysis. PLoS One. 2015 Aug 5;10(8):e0134589. doi: 10.1371/journal.pone.0134589. PMID: 26244843; PMCID: PMC4526635.
17: Guay DR. Extended-release alfuzosin hydrochloride: a new alpha-adrenergic receptor antagonist for symptomatic benign prostatic hyperplasia. Am J Geriatr Pharmacother. 2004 Mar;2(1):14-23. doi: 10.1016/s1543-5946(04)90003-7. PMID: 15555475.
18: Elhilali MM. Alfuzosin: an alpha1-receptor blocker for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. Expert Opin Pharmacother. 2006 Apr;7(5):583-96. doi: 10.1517/14656566.7.5.583. PMID: 16553574.
19: Kirby RS. Clinical uroselectivity of alfuzosin in the treatment of benign prostatic hyperplasia. Eur Urol. 1998;33 Suppl 2:19-27. doi: 10.1159/000052230. PMID: 9556192.
20: Maia NPD, Lopes KC, Ganança FF. Otorhinolaryngological adverse effects of urological drugs. Int Braz J Urol. 2021 Jul-Aug;47(4):747-752. doi: 10.1590/S1677-5538.IBJU.2021.99.06. PMID: 33566468; PMCID: PMC8321485.
